Article Details
Retrieved on: 2025-09-29 18:50:02
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
With the acquisition, Novartis gains Tourmaline's pacibekitug, an anti-interleukin 6 (IL-6) monoclonal antibody (mAb), in development as a treatment ...
Article found on: www.biopharminternational.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here